ACADIA Pharmaceuticals (ACAD) stock had a bullish inflow of $25.9 million worth of trades on uptick and an outflow of $24.26 million in downticks on Wednesday. The total uptick to downtick ratio stood at 1.07. The net money flow into the stock was $1.63 million. The money flow data, which is calculated as the dollar value of composite uptick minus the downtick trades indicated bullish. The block trades had a total money flow of $0.91 million. An inflow of $0.44 million block trade was recorded on downticks. $1.35 million of block trade during Uptick was observed, which shows continued buying by the smart money on every weakness. The total uptick to downtick ratio of block trades was 3.06 in favor of the bulls. However, ACADIA Pharmaceuticals (ACAD) stock traded down $1.43 , and reached $33.8, a drop of -4.06% over the previous day. On a weekly basis, the stock is -3.37%, over the previous weeks close.
ACADIA Pharmaceuticals Inc. has dropped 5.45% in the last five trading days, however, the shares have posted positive gains of 3.25% in the last 4 weeks. ACADIA Pharmaceuticals Inc. is up 4.01% in the last 3-month period. Year-to-Date the stock performance stands at -5.53%.
ACADIA Pharmaceuticals (ACAD) : Zacks Investment Research ranks ACADIA Pharmaceuticals (ACAD) as 3, which is a Hold recommendation. 4 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 2 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 6 research analysts is 1.67, which indicates as a Buy.
ACADIA Pharmaceuticals (NASDAQ:ACAD): stock was range-bound between the intraday low of $33.25 and the intraday high of $35 after having opened at $34.95 on Wednesdays session. The stock finally closed in the red at $34.95, a loss of -4.40%. The stock remained in the red for the whole trading day. The total traded volume was 3,639,257 shares. The stock failed to cross $35 in Wednesdays trading. The stocks closing price on Thursday was $35.23.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Companys drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinsons disease psychosis, Alzheimers disease psychosis, Schizophrenia and Sleep disturbances. The Company is also conducting preclinical programs for alpha adrenergic agonists indicated for the treatment of chronic pain and muscarinic drugs for the treatment of glaucoma. NUPLAZID has an active ingredient pimavanserin, is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that was discovered by the Company. The Company in collaboration with Allergan, has discovered and engaged in the development of small-molecule product candidates, such as alpha adrenergic agonists and muscarinic receptors.